This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.

Inclusion Criteria:

• Male and female subjects
• 18 years and older
• Histologic confirmation of advanced solid tumors
• Subjects must have recurrent/metastatic disease and may have been previously treated in the recurrent/metastatic setting.

Exclusion Criteria:

• Any concurrent chemotherapy, immune-mediated therapy or biologic or hormonal therapy for cancer treatment
• Active or prior documented autoimmune disease within the past 2 years
• Current or prior use of immunosuppressive medication within 14 days with some exceptions.